Agreement provides for development and promotion of OraQuick HCV test outside of the U.S.
Schering-Plough and OraSure Technologies will collaborate on the development and promotion of a rapid, oral hepatitis C virus (HCV) test utilizing OraSure Technologies’ OraQuick® technology platform on a worldwide basis outside the U.S.
Under terms of the agreement, Schering-Plough will reimburse OraSure for certain development costs and will provide payments to OraSure based on the achievement of certain regulatory and commercial milestones in international markets.
Schering-Plough will also provide promotional support for the product in international markets. All sales of the HCV test will be made by OraSure, and the company will retain the rights to market and sell the test in all markets throughout the world. During the collaboration period, the test may, at Schering-Plough’s option, be labeled and promoted under both Schering-Plough and OraSure trademarks.
This new agreement expands the existing collaboration announced in January 2007 when the parties signed an agreement to develop and promote a rapid, oral HCV test in the U.S. physicians’ office markets.
